← boardnext 2027-05-27
MBX
MBX Biosciencesdistress 2/10 · well-funded / low risk$59.27+2%today-10% from 52w high
Nephrology 1
Lead: obesity · est. market ~$15B (approx, global)
Revenue
pre-revenue
Liquidity
$440M
Runway
5.7 yrs
Shares 1y
+42%
Price & events
+39.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
+1.7%
1D
+1.6%
1W
+27.8%
1M
+77.5%
3M
+56.6%
6M
+333.3%
1Y
—
2Y
—
5Y
+150.6%
All
Overview
- Market Cap
- $2.82B
- Volume
- 30.61K
- 52 Week Range
- $9.74 – $65.71
- Total Shares
- 47.60M
- Float Shares
- 27.05M
- Short %
- 17.38%
- % Held by Insiders
- 2.70%
- % Held by Institutions
- 120.59%
- RVOL
- 0.03x
Pipeline stages · 3 programs
400 µg of MBX 2109 once-weekly by subcutaneous injection, 200-1600 µg of MBX 2109 once-wee
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
MBX 2109, MBX 2109, MBX 2109, MBX 2109
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
MBX 1416 (INN imapextide)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 4 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-05-27 Estimated 50% readout ~2027-07-11 | Phase 2 | 400 µg of MBX 2109 once-weekly by subcutaneous injection, 200-1600 µg of MBX 2109 once-wee | Hypoparathyroidism | — | active not recruiting |
| 2025-12-22 | Phase 2 | MBX 1416 (INN imapextide) | Postbariatric Hypoglycemia | 10 | recruiting |
| 2025-09-04 | Phase 1 | MBX 2109, MBX 2109, MBX 2109, MBX 2109 | Renal Impairment | 25 | completed |
| 2025-05-23 | Phase 2 | MBX 2109 | Hypoparathyroidism | 64 | completed |
Upcoming readouts & decisions · our signals
1 upcoming event has our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.
Catalyst news & presentations · 13
- 2027Guided 40%readoutPhase 1MBX 4291 · Topline results of Phase 1 clinical trial anticipated in 2027SEC 8-K
- Q4 2026Guided 70%readoutPhase 1MBX 4291 · 12-week multiple ascending dose data from Phase 1 trialSEC 8-K
- 2026Guided 40%trial initiationsecondaryPhase 3canvuparatide · Plan to initiate Phase 3 clinical trial of once-weekly canvuparatideSEC 8-K
- Q3 2026Guided 70%trial initiationsecondaryPhase 3canvuparatide · Initiation of Phase 3 confirmatory trialSEC 8-K
- Q4 2026Guided 70%readoutPhase 1MBX 4291 · Data from 12-week MAD Part C cohortSEC 8-K
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- Q2 2026readoutPhase 2canvuparatide · One-year follow-up data from Phase 2 Avail trialSEC 8-K
- Q2 2026readoutPhase 2imapextide · Results from Phase 2a STEADI trialSEC 8-K
- January 13, 2026 at 3:45 pm PTconferencedata presentationsecondaryCorporate presentation at 44th Annual J.P. Morgan Healthcare ConferenceSEC 8-K
- second half of 2025trial initiationsecondaryPhase 2MBX 1416 · Initiate Phase 2 study in patients with PBHSEC 8-K
- Q3 2025readoutPhase 2canvuparatide (MBX 2109) · Phase 2 topline resultsSEC 8-K
- Q3 2025trial initiationsecondaryPhase 1MBX 4291 · Phase 1 trial in healthy overweight volunteers expected to initiate.SEC 8-K
- Q2 2025regulatory submissionFiled (NDA/BLA)MBX 4291 · IND submissionSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $69 (+16% upside) · 11 analysts
- 2026-05-12BarclaysOverweight
- 2026-05-12CitizensMarket Outperform
- 2026-05-11Truist SecuritiesBuy
- 2026-01-28BarclaysOverweight
- 2026-01-16GuggenheimBuy
- 2026-01-07UBSBuy
Competitors — obesity
- LLYELI LILLY & Co$1094.4B · D3
- AMGNAMGEN INC$195.4B · D3
- GPCRStructure Therapeutics Inc.$11.2B · D4
- RYTMRHYTHM PHARMACEUTICALS, INC.$7.0B · D0
- WVEWave Life Sciences Ltd.$1.1B · D1
- CRBPCorbus Pharmaceuticals Holdings, Inc.$164M · D7
- GUTSFRACTYL HEALTH, INC.$123M · D9
- VANIVivani Medical, Inc.$118M · D7
- MTVAMetaVia Inc.$8M · D7
- NONOFNOVO NORDISK A S— · D2
Recent news
- 2026-07-20MBX Biosciences (MBX) price target increased by 11.23% to 69.55 - MSN
- 2026-07-20MBX Biosciences (MBX) price target increased by 11.23% to 69.55 - MSN
- 2026-07-18MBX Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
- 2026-07-17MBX Biosciences (NASDAQ:MBX) Trading 5.1% Higher - What's Next? - MarketBeat
- 2026-07-17Is MBX Biosciences (MBX) Fairly Valued As New Leadership Takes Charge? - Sahm
- 2026-07-15How MBX Biosciences’ New CEO-Chairman Structure Could Reframe the MBX Investment Narrative - Sahm
- 2026-07-15Goelzer Investment Management, Inc.'s MBX Biosciences Inc(MBX) Holding History - GuruFocus
- 2026-07-15FMR LLC's Strategic Acquisition of MBX Biosciences Inc Shares - GuruFocus
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.